AbbVie (ABBV)

Executive Summary

AbbVie is a global biopharmaceutical leader with a market valuation exceeding $376 billion, focused on immunology, oncology, neuroscience, eye care, and virology. The company has successfully navigated the Humira biosimilar erosion by leveraging its next-generation portfolio, including Skyrizi (risankizumab) and Rinvoq (upadacitinib), which have driven robust revenue growth. With 36 approved products and a deep pipeline across multiple modalities, AbbVie is well-positioned to sustain its leadership. Key upcoming catalysts include potential label expansions for Skyrizi in ulcerative colitis and Rinvoq in giant cell arteritis, as well as ongoing Phase 3 readouts for emraclidine in schizophrenia. These events could provide significant upside and reinforce AbbVie's pipeline strength, though Humira's continued decline remains a near-term headwind. The company's strategic focus on high-growth areas and its strong balance sheet support its ability to pursue business development and internal innovation.

Upcoming Catalysts (preview)

• Q3 2026FDA approval of Skyrizi for ulcerative colitis80% success
• H2 2026Rinvoq label expansion for giant cell arteritis (SELECT-GCA data)70% success
• Q4 2026Emraclidine Phase 2 readout in schizophrenia60% success